About
Femasys Inc. is a biomedical company based in Suwanee, Georgia, focused on developing innovative therapeutic and diagnostic solutions for women's healthcare. Founded in 2004, the company aims to address unmet healthcare needs through minimally invasive, in-office technologies that enhance the standards of care in female reproductive health. The product portfolio includes FemaSeed, an intratubal insemination solution; FemVue, a diagnostic tool for fallopian tube assessment; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for fallopian tube evaluation; FemChec, a device for fallopian tube diagnosis; and FemBloc, a non-surgical permanent birth control solution recently approved in Europe. Femasys serves reproductive endocrinologists, gynecological physicians, and women's healthcare organizations, emphasizing safety and innovation in its offerings. Led by CEO Kathy Lee-Sepsick, Femasys holds approximately 200 patents globally and has reported significant sales growth, reaching $3.0 million in 2024. The company continues to invest in innovation and market development to enhance women's reproductive healthcare.
Technologies
Keywords
Company Information
-
Employees 69
-
Founded 2004
-
Annual Revenue $1699000
-
Total Funding $112146700
Location
3950 Johns Creek Ct, Suwanee, Georgia, United States, 30024